Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.

[1]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[2]  D. Kalanovic,et al.  Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach , 2010, World Journal of Urology.

[3]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Ravaud,et al.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Cath Taylor,et al.  Multidisciplinary team working in cancer: what is the evidence? , 2010, BMJ : British Medical Journal.

[7]  R. Nation,et al.  A Palliative Cancer Care Flexible Education Program for Australian Community Pharmacists , 2010, American Journal of Pharmaceutical Education.

[8]  T. Miki,et al.  A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. , 2010, Japanese journal of clinical oncology.

[9]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Edmonds,et al.  Managing adverse events associated with sorafenib in renal cell carcinoma. , 2010, British journal of nursing.

[11]  P. Creel.  Management of mTOR inhibitor side effects. , 2009, Clinical journal of oncology nursing.

[12]  C. Porta,et al.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.

[13]  T. Fujioka,et al.  Evidence‐based clinical practice guidelines for renal cell carcinoma (Summary – JUA 2007 Edition) , 2009, International journal of urology : official journal of the Japanese Urological Association.

[14]  T. D. de Reijke,et al.  EORTC-GU group expert opinion on metastatic renal cell cancer. , 2009, European journal of cancer.

[15]  D. Lenihan,et al.  Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Belldegrun,et al.  Cancer‐specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989‐2005) , 2008, Cancer.

[17]  M. Halushka,et al.  Heart failure associated with sunitinib malate , 2008, Cancer.

[18]  D. Lenihan,et al.  Sunitinib-related cardiotoxicity: an interdisciplinary issue , 2008, Nature Clinical Practice Cardiovascular Medicine.

[19]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[20]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[21]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[22]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Susan Catt,et al.  Multidisciplinary teams in cancer care: are they effective in the UK? , 2006, The Lancet. Oncology.

[24]  M. Tattersall,et al.  Multidisciplinary team meetings: where is the value? , 2006, The Lancet. Oncology.

[25]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[26]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Figlin,et al.  Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. , 2003, The Journal of urology.

[28]  G. Roos,et al.  Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. , 1995, The Journal of urology.

[29]  Jean-Jacques Patard,et al.  EAU guidelines on renal cell carcinoma: the 2010 update. , 2010, European urology.

[30]  L. Wood.  New therapeutic strategies for renal cell carcinoma. , 2010, Urologic nursing.

[31]  M. Prince-Paul,et al.  The effects of integrating an advanced practice palliative care nurse in a community oncology center: a pilot study. , 2010, The journal of supportive oncology.

[32]  M. Aapro,et al.  The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. , 2009, Critical reviews in oncology/hematology.

[33]  Lorenzo Marconi,et al.  Guidelines on Renal Cell Carcinoma , 2007 .

[34]  N. Vogelzang.  Treatment options in metastatic renal carcinoma: an embarrassment of riches. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Bernd Blobel,et al.  Results of European Projects Improving Security of Distributed Health Information Systems , 1998, MedInfo.